Article Sidebar

PDF
Date Published: 21/06/2022
Abstract Views: 640
Views PDF: 307
DOI: https://doi.org/10.51298/vmj.v514i2.2626
Issue
Vol. 514 No. 2 (2022)
Section
Các bài báo
How to Cite
Huy Thịnh, T. ., Hoàn, L. ., & Vân Khánh, T. . (2022). IDENTIFICATION OF EGFR MUTATION AND EML4-ALK, ROS1 FUSION GENE IN NON SMALL CELL LUNG CANCER. Vietnam Medical Journal, 514(2). https://doi.org/10.51298/vmj.v514i2.2626

IDENTIFICATION OF EGFR MUTATION AND EML4-ALK, ROS1 FUSION GENE IN NON SMALL CELL LUNG CANCER

Trần Huy Thịnh1,, Lê Hoàn1, Trần Vân Khánh1
1 Hanoi Medical University

Main Article Content

Abstract

Targeted therapy is an effective method for treatment of non small cell lung cancer (NSCLC), especially in patients group carrying EGFR, EML4-ALK, ROS1 mutation. However, not all of patients have good response with targeted drugs. Many previous studies demonstrated the close relationship between EGFR and EML4-ALK, ROS1 rearrangement mutation and the response of targeted drugs with tumor. Objectives: Identifying EGFR mutation and EML4-ALK, ROS1 rearrangement mutations in NSCLC patients by realtime PCR and FISH methods. Methods: 135 NSCLC patients were selected for this study; realtime PCR and FISH methods were used to identify EGFR mutation and EML4-ALK, ROS1 rearrangement mutation. Results: 69/135 (51,1%) of NSCLC patients have mutation in exon 19, 20 and 21 of EGFR gene; 9/135 (6,7%) of NSCLC patients have EML4-ALK rearrangement mutation and 3/135 (2,2%) of NSCLC patients have ROS1 rearrangement mutation.

Article Details

Keywords

Non small cell lung cancer, EGFR mutation, EML4-ALK, ROS1 rearrangement mutation, Targeted therapy

References

1. Jemal A, Bray F, Ward E. et al (2011), “Global cancer statistics”, CA Cancer J Clin, 61(2), 69-90.
2. Sato M, Shames DS, Gazdar AF, Minna JD (2007). A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol. 2:327-43.
3. Wistuba II, Mao L, Gazdar AF (2002). Smoking molecular damage in bronchial epithelium. Oncogene. 21,7298-306.
4. Lee CK, Brown C, Gralla RJ et al. Impact of EGFR inhibitor in non–small cell lung cancer on progression-free and overall survival: a meta-analysis. Journal of the National Cancer Institute 2013; 105: 595-605.
5. Martelli MP, Sozzi G, Hernandez L, et al. (2009), "EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues", Am J Pathol, 174 (2), pp. 661-70.
6. Sébastien Gendarme, Olivier Bylicki, Christos Chouaid and Florian Guisier (2022). ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. Curr. Oncol. 29, 641–658
7. Tam I.Y., Leung E.L., Tin V.P. et al (2009). Double EGFR mutants containing rare EGFR mutants types show reduced in vitro response to gefitinib compared with common activating missense mutations. Mol Cancer Ther., 8, 2142-2151.
8. Ngô Quý Châu, Chu Thị Hạnh, Trần Vân Khánh, Lê Hoàn (2014). Dung hợp gen EML4-ALK: Hướng tiếp cận mới trong điều trị nhắm trúng đích với ung thư phổi không tế bào nhỏ. Y học lâm sàng, 77, 11-16.